World's Most Broad-Spectrum Antibiotic Available OTC

A new topical antibiotic formulation, known as Tetracycline-ABC kills the most drug-resistant and the most deadly bacteria (Staph, MRSA and Acinetobacter), which cause community or hospital acquired infections. End Quote

(1888PressRelease) October 13, 2010 - The availability of a new topical antibiotic formulation, known as Tetracycline-ABC, was announced today. The new liquid antibiotic is available as an OTC drug by Phillips Company, an FDA-registered pharmaceutical manufacturer.

The manufacturer believes this is the world's strongest broad-spectrum topical antibiotic. It is based on TETRA-ABC, previously developed for use as a barrier-protection ointment. It kills the most drug-resistant and the most deadly bacteria (Staph, MRSA and Acinetobacter), which cause community or hospital acquired infections. The Tetracycline-ABC topical antibiotic kills all other harmful Gram positive and Gram negative bacteria that have been available for testing.

The new antibiotic formulation is based on tetracycline, the world's most-used broad-spectrum antibiotic, according to Steve Keough, a spokesman for Phillips Company. In-vitro tests, in controlled laboratory conditions, have shown that the Zone of Inhibition or kill zone is significantly larger than the area where the product is applied. Keough further added, "Tetracycline-ABC topical antibiotic is clearly a best in class pharmaceutical solution, with applications across multiple fields of use."

Most older antibiotics require a few days of treatment for best results. Tetracycline-ABC is an improvement over older antibiotics in this class because of a carrier formulation that speeds the active ingredient deep into the cell structure of a wound.

Liquid versions of older tetracycline were not commercially available because the shelf life of this drug was limited to a few weeks for water-based tetracycline liquid medicines. Phillips Company has solved this problem with a patent-pending formulation using advanced chemistry.

Tetracycline-ABC will be licensed to a larger company for manufacturing and commercialization. Phillips Company is a small pharmaceutical development company with manufacturing capacity limited to 50,000 units per month. Using the develop-and-license business model, the company has licensed six pharmaceutical products in 2010.

Licensing inquiries: http://www.PhillipsCompany.4T.com

###

Visit Phillips Company Website

space